Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rosaria Sancetta
Observed names:
Sancetta Rosaria,
Sancetta, Rosaria
Institution:
Ospedale dell' Angelo
Observed institutions:
University of Udine,
Ospedale dell' Angelo,
Policlinico San Matteo Fondazione,
Ospedale di Macerata,
Azienda sanitaria universitaria Friuli Centrale
OpenAlex ID:
A5036411593
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
2006
·
Andrea Gallamini
, Luigi Rigacci
, et al.
·
PubMed
·
314
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
2019
·
Simona Soverini
, Luana Bavaro
, et al.
·
Blood
·
113
PDF
Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi
2007
·
Luigi Rigacci
, Umberto Vitolo
, et al.
·
Annals of Hematology
·
113
Burkitt lymphoma in adolescents and young adults: management challenges
2016
·
Massimo Dozzo
, Francesca Carobolante
, et al.
·
Adolescent Health Medicine and Therapeutics
·
109
PDF
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
2019
·
Michele Baccarani
, Elisabetta Abruzzese
, et al.
·
Blood Advances
·
89
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
2020
·
Massimo Breccia
, Elisabetta Abruzzese
, et al.
·
Leukemia
·
63
PDF
The prognostic value of positron emission tomography performed after two courses ( INTERIM‐PET ) of standard therapy on treatment outcome in early stage H odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)
2015
·
Luigi Rigacci
, Benedetta Puccini
, et al.
·
American Journal of Hematology
·
53
PDF
Current and future management of Ph/BCR-ABL positive ALL
2014
·
Elena Maino
, Rosaria Sancetta
, et al.
·
Expert Review of Anticancer Therapy
·
49
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report
2021
·
Massimo Breccia
, Elisabetta Abruzzese
, et al.
·
British Journal of Haematology
·
26
PDF
Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia
2017
·
Renato Bassan
, Tamara Intermesoli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
25
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
2021
·
Michele Malagola
, Alessandra Iurlo
, et al.
·
Cancer Medicine
·
21
PDF
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
2023
·
Luca Lanino
, Francesco Restuccia
, et al.
·
American Journal of Hematology
·
20
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
2018
·
Mario Tiribelli
, Massimiliano Bonifacio
, et al.
·
Oncotarget
·
19
PDF
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice
2013
·
Francesco Zaja
, Michael Mian
, et al.
·
American Journal of Hematology
·
15
Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population
2025
·
Massimo Breccia
, Antonella Russo Rossi
, et al.
·
Hematological Oncology
·
14
PDF
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study
2020
·
Andrea Visentin
, Vincenzo Nasillo
, et al.
·
HemaSphere
·
14
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia
2013
·
Mario Tiribelli
, Massimiliano Bonifacio
, et al.
·
Leukemia Research
·
14
Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL
2022
·
Lydia Scarfò
, Silvia Heltai
, et al.
·
Blood
·
12
PDF
Modern Immunotherapy of Adult B-lineage Acute Lymphoblastic Leukemia With Monoclonal Antibodies and Chimeric Antigen Receptor Modified T Cells
2014
·
Elena Maino
, Anna Maria Scattolin
, et al.
·
Mediterranean Journal of Hematology and Infectious Diseases
·
11
PDF
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
2024
·
Michele Malagola
, Alessandra Iurlo
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
10
PDF
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
2023
·
Mario Tiribelli
, Roberto Latagliata
, et al.
·
Cancer
·
10
PDF
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers
2025
·
Elena Crisà
, Daniela Cilloni
, et al.
·
Cancers
·
8
PDF
P686: Real-world Efficacy Profile of Asciminib in an Italian, Multi-resistant Chronic-phase Chronic Myeloid Leukemia (cp-cml) Patient Population
2023
·
Massimo Breccia
, Antonella Russo Rossi
, et al.
·
HemaSphere
·
6
Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study
2020
·
Lydia Scarfo
, Silvia Heltai
, et al.
·
Blood
·
6
Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing
2018
·
Simona Soverini
, Luana Bavaro
, et al.
·
Blood
·
5
Show more works
View as search
Works count:
42
Citation count:
1,149
H-index:
14
I10-index:
21
Year
Topic
Type